Introduction
Xylazine (5,6-dihydro-2-(2,6-xylidino)-4H-1,3-thiazine) was first synthesized in 1962 as an antihypertensive drug in Germany by Bayer Corporation. It shares certain pharmacological properties with a number of structurally related drugs: phenothiazines, tricyclic antidepressants and clonidine (1) . Today, xylazine is a non-narcotic drug used in veterinary medicine as a sedative, analgesic and muscle relaxant for large animals, such as deer, ruminants and horses ( Figure 1 ).
Xylazine was investigated in humans as a sedative-hypnotic, analgesic and anesthetic drug, but it was rejected because of its frequent association with severe hypotension (2) . Several cases of xylazine intoxication in people have been reported. To our knowledge, 27 cases of toxicity caused by xylazine consumption have been documented in humans. According to these reported cases, consumption was accidental, for suicidal or homicidal purposes, or used as an agent of drug abuse, with more than 50% of uses resulting in death. In humans, it causes bradycardia, central nervous system depression, respiratory depression and severe hypotension and its chronic use is reported to be associated with physical deterioration when used as an adulterant (1 -19) .
Xylazine is known as "anestesia de caballo" (horse anesthetic) in Puerto Rico and has been found as an adulterant of heroin in street drugs since 2000 (19) . In 2007, a total of 663 street heroin samples were analyzed by the Controlled Substances Section at the Institute of Forensic Sciences of Puerto Rico (PRIFS). Some of the more common non-opiate cutting agents encountered with pharmaceutical effects were: caffeine (23%), procaine (3%), cocaine (5%), quinine (10%), lidocaine (3%) and the most frequently detected, xylazine (36%). Other cutting agents were found less frequently (,3%) than the aforementioned compounds. Xylazine detection in the street heroin samples for 2007 (36%) was similar to 2006 (36%), showing a recurrence of xylazine as the major adulterant used with heroin. Xylazine was not only found as an adulterant of heroin, but was also found as the only component or in combination with other drugs such as caffeine, cocaine, lidocaine and quinine (20, 21) . According to our experience, xylazine continues to be the major adulterant of street heroin.
Heroin alone has proven dangerous to humans and its combination with xylazine can be even more harmful in terms of toxicity. Literature shows some similar pharmacologic effects between xylazine and heroin in humans. Both drugs cause bradycardia, hypotension, central nervous system depression and respiratory depression (14, 22 -26) . Due to these similar pharmacologic effects, synergistic effects may occur in humans.
In addition, xylazine was found in combination with one or more compounds such as free morphine and 6-acetylmorphine (6-AM), codeine, cocaine and benzoylecgonine (BE) in nine postmortem cases between 2003 and 2007 at the PRIFS in an unpublished study by Chavez et al. (27) . Xylazine was associated with the cause of death in all of these cases (27) .
Currently, different analyses are required to confirm and quantify the aforementioned drugs at the PRIFS's toxicology laboratory. The analysis of xylazine is performed using protein precipitation and liquid chromatography -mass spectrometry (LC -MS). This procedure is only performed at the pathologist's request, so xylazine is not routinely monitored in all postmortem cases. The analyses for free morphine, 6-AM, codeine, cocaine and BE are performed using solid-phase extraction (SPE) and gas chromatography -mass spectrometry (GC -MS). A large amount of sample is used and procedures are laborintensive and time consuming due to sample preparation.
To optimize workflow and reduce analysis time consumption, sample volume, run time, sample preparation and cost, a multi-target method that simultaneously detects xylazine, free morphine, 6-AM, codeine, cocaine and BE was developed using validated ultra-high-pressure liquid chromatography-electrospray ionization (UPLC -ESI) on a triple-quadrupole tandem mass spectrometer using multiple reaction monitoring (MRM) mode. This method was developed using a small sample volume of postmortem blood (0.25 mL), pretreated for protein precipitation with acetonitrile and requiring a total run time of 2.5 min. No derivatization of the analytes is required. Sample preparation and run time analysis shows this method suitable for high-throughput bioanalytical applications. To our knowledge, this is the first method by UPLC-MS-MS used for the simultaneous detection of these compounds. The validated methodology fosters efficiency in applications to routine casework within a forensic toxicology setting, especially when the sample amount is not sufficient for analysis by current methodologies.
Experimental

Standards and reagents
Morphine, 6-AM, codeine, nalorphine, cocaine, cocaine-d3, BE and BE-d3 at 1 mg/mL were obtained from Cerilliant (Round Rock, TX). Xylazine was purchased from Sigma-Aldrich (St-Louis, MO) as a powder. All standard materials were of high purity (.98.0%). All reagents were HPLC grade. Acetonitrile (ACN) and methanol (MeOH) were purchased from Fisher Scientific (Fairlawn, NJ). Formic acid (96%) was obtained from Spectrum Chemical MFG Corp. (Gardena, CA). Deionized water was generated with Elix, Millipore water purification systems (Millipore Corp., Molscheim, France). Bovine blood was used to prepare blanks, calibrators, and quality control (QC) samples.
Preparation of standard solutions, calibrator, and QC samples A stock solution of xylazine at 0.5 mg/mL was prepared in methanol. Morphine, 6-AM, codeine, cocaine and BE at 1 mg/mL were used as a stock solutions. A working calibration solution containing xylazine, morphine, 6-AM, codeine, cocaine and BE was prepared from stock solutions at 0.1, 2 and 50 mg/L to prepare the calibration samples. A working QC containing xylazine, morphine, 6-AM, codeine, cocaine and BE was prepared from stock solutions at 0.1, 2 and 50 mg/L to prepare QC samples. Nalorphine at 0.5 mg/mL in methanol, and cocaine-d3 and BE-d3 at 100 mg/L in methanol were used to prepare a mixed internal standard (IS) working solution in acetonitrile at 0.2 mg/L. A ten-point calibration curve (10, 20, 50, 80 , 100, 150, 250, 500, 750 and 1,000 ng/mL) was prepared for the routine analysis by adding the appropriate amount of working calibrator to 1.0 mL bovine blood. Four QCs (10, 50, 500 and 800 ng/mL) were prepared by adding the appropriate amount of QC working solutions to 1.0 mL bovine blood.
Sample preparation
All samples (including calibrators and QCs) were vortex-mixed briefly and aliquots (0.25 mL) were transferred to microcentrifuge tubes. Proteins were precipitated by the addition 0.75 mL of acetonitrile containing the IS mixture (0.2 mg/ L). Following precipitation, tubes were vortex-mixed for 10 s and placed in the deep-freezer at -208C for a minimum of 10 min, then centrifuged at 8,000 rpm for 10 min. The supernatant (0.5 mL) was collected and evaporated to dryness by using a centrifugal vacuum concentrator (Labconco Centrivap, Labequip, Ontario, Canada). The dry residue was then reconstituted with 0.1 mL of 0.1% formic acid water, centrifuged at 4,000 rpm for 2 min, and transferred to autosampler vials.
UPLC-MS-MS
A triple quadrupole (TQD) mass spectrometer with an orthogonal electrospray ionization source to Z-spray (Waters, Milford, MA) coupled to a UPLC system was used in positive ESI mode. Chromatographic separation was carried out using an Acquity UPLC HSS T3 column (50 Â 2.1 mm i.d., particle size 1.8 mm) (Waters) with a column temperature of 458C. A column in-line filter (Waters) was used in front of the column. The injection volume and injection mode were 10 mL and full loop, respectively. An optimized gradient was used at a flow rate of 0.5 mL/ min using 0.1% formic acid in water (A) and acetonitrile (B). The gradient was performed according to the elution program described in Table I . The total run time was 2.5 min.
The MS-MS parameters were developed automatically with MassLynx v 4.1 software and IntelliStart (Waters). MS-MS parameters were optimized by direct infusion of individual standard solutions at 1 mg/L in methanol at a flow rate of 5 mL/min. The molecular ion mass was entered into IntelliStart and the software automatically determined the optimized cone voltage for the precursor mass, three product masses and their corresponding collision energies. A report was automatically generated for each compound, specifying the optimized settings for the MRM method. The report also detailed the daughter ion spectra along with cone voltage and collision energy values. Table II summarizes the MS-MS conditions for six analytes and ISs.
The capillary was set at 3.30 kV. The source and desolvation temperature were set at 150 and 4508C, respectively. The cone and desolvation gas flow were set at 20 and 900 L/Hr, respectively. The collision gas (argon) flow was set at 0.15 mL/min. Data were acquired in MRM mode using one precursor ion/ three product ion transitions for each target analyte and one precursor ion/two product ion transitions for each IS. The most prominent MRM transitions were used for quantification and the others as qualifiers. All data were acquired and processed using MassLynx v 4.1 software and TargetLynx (Waters) application manager.
Method Validation
Validation parameters included linearity, limit of detection (LOD) and limit of quantification (LOQ), intra-day and inter-day precision and accuracy, process efficiency, recovery, matrix effect, selectivity, carryover and stability of the working solutions. Linearity was determined using six calibrators in a concentration range of 10 to 1.000 ng/mL in five replicates. The calibration curve was generated using the peak area ratio of each analyte and IS versus concentration. Acceptable linearity was achieved when the coefficient of determination was at least 0.99 and calibrators quantified within +20% at the LOQ and +15% at other concentrations. LOD and LOQ were evaluated with decreasing analyte concentration in drug-fortified bovine blood. LOD was defined as the lowest concentration with acceptable chromatography, presence of the quantifier ion with a mean area response of the blanks plus three standard deviations, presence of all ions with signal-to-noise ratios of at least 3, retention time (RT) within +0.2 min of the average calibrator RT, and the lowest concentration at which all fortified samples had a relative ion intensity ratio +20% from the mean ion ratio intensity of calibrators. The LOQ was defined as the lowest concentration meeting the quantitative acceptance criteria ( precision ,20% and accuracy within +20% of the target value) and the lowest concentration at which all fortified samples have relative ion intensity ratio +20% from the mean ion ratio intensity of calibrators.
Inter-day and intra-day precision and accuracy of the assay was assessed over three separate days using five replicates of each QC (10, 50, 500 and 800 ng/mL). Acceptable accuracy was based on the mean measured value falling within 15% of the fortified target value, except for the LOQ, for which it should not exceed 20%. Acceptable precision was based on the mean measured value falling within 15% of the coefficient of variation (%CV), except for the LOQ, for which it should not exceed 20%.
The process efficiency (PE), recovery (RE) and matrix effect (ME) were evaluated using the methods described by Matuszewski et al. (28) . Mean peak area responses for target quantification MRM transitions for each compound were used to calculate PE, RE and ME.
RE was determined by comparing mean peak areas of blank bovine blood specimens fortified with analytes before extraction (n ¼ 5 at a concentration of 60 and 600 ng/mL) with those obtained in specimens fortified with the same compounds after extraction (n ¼ 5 at a concentration of 60 and 600 ng/mL). RE was calculated as follows: 100 Â mean peak area of pre-extraction spike/mean peak area post-extraction spike. ME (ion suppression and ion enhancement) was determined by comparing mean peak areas in nine different blood extracts originating from nine different sources fortified after extraction to those obtained when the same amount of analytes and IS were added to a clean tube, evaporated and reconstituted in 0.1 mL 0.1% formic acid water (n ¼ 9). The nine different sources were collected from negative postmortem cases and samples were analyzed once at concentrations of 60 and 600 ng/mL for each target analyte. Matrix suppression or enhancement was calculated as follows: % effect ¼ (100 Â mean peak area of post-extraction spike/mean peak area of neat) 100. PE was calculated by comparing mean peak areas of negative bovine blood samples fortified before extraction to those obtained when the analytes were added to a clean tube (n ¼ 5 at concentrations of 60 and 600 ng/mL). PE was calculated as follows: 100 Â average peak area of pre-extraction spike/mean peak area of neat.
The method's selectivity was assessed by the analysis of six whole blood blank samples of different origin. The acceptance criteria for interferences at the retention time of the analyte of interest were defined as a signal-to-noise ratio , 3. To examine the interferences from other possible drugs in forensic cases, standard solutions of 1 mg/L in 0.1% formic acid containing common drugs, including benzodiazepines, amphetamines, analgesics, antidepressants, antipsychotics, barbiturics, antiepileptics, antihistamines, antiarrhythmics, antitussives and cardiovascular and muscle relaxants were tested for their contribution to positive blank values. The following drugs were examined: amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital, phenytoin, carbamazepine, lamotrigine nordiaze- Lack of carryover was demonstrated by injecting IS-fortified bovine blank blood immediately after a sample spike with all analytes at 1,000 ng/mL (the upper LOQ). Carryover was considered negligible if the measured concentration was below the LOD.
The stability of working solutions was evaluated for a relevant period of time of eight months. Two different concentrations of working solutions at 2 and 50 mg/L were tested in triplicate preparation without extraction. Old working solutions at the concentrations mentioned previously were compared with freshly prepared solutions at the same concentration. Stability was tested by comparing analyte mean area response in old solutions with freshly prepared solutions.
The percent difference was calculated and the acceptance criteria should be 10%.
Identification criteria
Identification criteria included retention time within +0.2 min of average calibrator retention time, presence of all transitions and relative ion intensities ( percent of base peak) within +20%, if relative ion intensity was .50%; +25% if 20 -50%; +30% if 10-20%; and +50% if 10% (29, 30) . Relative ion intensities were calculated based on ion ratios of two transitions (most abundant transition divided by less abundant) 221. 13 
Method application
The developed method was successfully applied to drug intoxication cases from the PRIFS. Collected specimens were cardiac blood from postmortem cases, which were placed in containers with sodium fluoride as preservative. Autopsy specimens were stored in the refrigerator (,88C) until analysis.
Results and Discussion
Analytical method A high throughput UPLC -MS-MS method with a total run of 2.5 min was developed and validated for the simultaneous quantification of xylazine, free morphine, 6-AM, codeine, cocaine and BE in 0.25 mL postmortem blood by protein precipitation, fulfilling confirmation criteria with three transition for each compound with acceptable relative ion intensities.
Validation data for linearity, LOD and LOQ are shown in Table III . Five calibration curves were prepared by spiking blank drug free bovine blood covering a range 10-1,000 ng/mL. Samples were processed and extracted as described earlier.
Quantitative results were obtained by integrating the peak area of the quantifier MRM transition to the integrated area of the internal standard at six different levels in five determinations.
A first order calibration curve (y ¼ ax þ b) was used for quantification of cocaine and BE. A second order calibration curve (y ¼ ax 2 þ bx þ c) was used for quantification of morphine, 6-AM, codeine and xylazine. Origin was excluded and a weighing factor 1/x was used for all analytes. The r 2 values were higher than 0.99 for all analytes. An LOD of 1 ng/mL for cocaine and xylazine, 2 ng/mL for 6-AM and 10 ng/mL for morphine, codeine and BE was determined experimentally from various spike concentration level samples. The LOQ for all compounds was 10 ng/mL. Figure 2 shows the quantitative ion chromatogram of extracted blank (Figure 2A ), 10 ng/mL control ( Figure 2B ) and postmortem case ( Figure 2C ) for each analyte.
Intra-day and inter-day precision and accuracy results for all tested concentrations were considered acceptable according to the FDA's guidelines for bionalytical method validation (31) ( Table IV) . Intra-day precision and accuracy was ,20% for the LOQ and ,15% for all QC samples. Inter-day precision and accuracy was ,20% for LOQ and ,15% for all QC samples. ME experiments were carried out to ensure that precision, accuracy, selectivity and sensitivity were not compromised. Some matrix effect was observed for all compounds with suppression or enhancement effects below 21% for all analytes except morphine, for which suppression at approximately 50% was observed. Variance in matrix effect (%CV) in negative postmortem blood specimens from nine different sources was ,15% at two concentrations, which is considered acceptable according to Viswanathan et al. (32) , except for morphine and BE. For morphine, only one concentration exhibited a %CV greater than 15%, and for BE, both concentrations exhibited a %CV greater than 15%; however, the results for linearity, precision and accuracy were acceptable for these compound. In the present method, nalorphine was used as an IS for free morphine, 6-AM and codeine; BE-d3 was used for BE; and cocaine-d3 was used for cocaine and xylazine. Data for RE, PE and ME are summarized in Table V .
Results for RE were .77% for all analytes, except for morphine, for which RE was . 59%. A similar situation was observed for PE, with values .70% in all cases except for morphine, for which PE was .35.9% (Table V) . However, a high RE or PE is not essential whenever reproducible results are observed for these parameters, and the sensitivity of the method is enough for its intended application.
Working solution stability data are presented in Table VI . The percent difference between the old working solutions and the fresh working solutions at two concentrations were less than 10% in all analytes.
Specimen analysis
The developed method was successfully applied to drug intoxication cases from the PRIFS. Figure 2C shows an example of a chromatogram with the quantitative transition of all analytes in a postmortem specimen. The decedent, a drug user, was found dead. The concentrations found in blood in this case were 743 ng/mL for free morphine, 24 ng/mL for codeine, less than 10 ng/mL for 6-AM, 65 ng/mL for cocaine and 461 ng/mL for xylazine. According to the literature, the dosages of xylazine known to produce toxicity and fatality in humans vary from 40 to 2,400 mg (3), with postmortem blood concentrations of xylazine ranging from trace to 16 mg/L and non-fatal blood or plasma concentrations ranging from 0.54 to 4.6 mg/L (1-18). Therefore, there is an overlap of postmortem concentrations between fatal cases and the non-fatal cases, which means there is no defined safe, toxic or fatal concentration. In addition, interpretation of results becomes even more difficult when xylazine is present in combination with other abused drugs.
Further studies need to be performed to establish the correlation between blood concentrations of xylazine with the presence of free morphine, 6-AM, codeine, cocaine and BE. These measurements will be important in determining the role of xylazine in the cause of death. The presence of free morphine, 6-AM, codeine, cocaine and BE in combination with xylazine in postmortem blood may be due to a cocaine and heroin mixture available in the illicit street market called "speedball" (19, 33) . Results from Rodriguez et al. revealed varying degrees of xylazine content in the illicit speedball preparations in different parts of Puerto Rico and conclude that xylazine users were more likely to be in poorer health than non-users (33) .
Therefore, the combination of xylazine and the typical drugs of abuse may increase fatalities among users. Adulteration of illicit drugs has become an epidemic health concern for drug users. Healthcare professionals need to be aware of this issue, so the patients can be treated in an effective, timely manner. Because free morphine, 6-AM, codeine, cocaine and BE were found in postmortem blood, further studies are suggested to increase the knowledge and understanding of this drug combination in humans.
Conclusions
A method for the simultaneous determination and quantification of xylazine, free morphine, 6-AM, codeine, cocaine and BE from postmortem blood was developed using protein precipitation and UPLC-MS-MS. The detection was performed on a TQD in MRM mode using positive ESI. Conditions for sample preparation and run time analysis along with validation parameters showed that this method is suitable for highthroughput bioanalytical applications. The method was applied in routine drug intoxication cases related to controlled substances.
